NCT03962049View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

October 23, 2019

Study Completion Date

November 1, 2019

Conditions
Hepatic ImpairmentHealthy Participants
Interventions
DRUG

Linzagolix

A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

Trial Locations (2)

32809

Clinical Site, Orlando

33014

Clinical Site, Hialeah

Sponsors

Lead Sponsor

ObsEva SA
All Listed Sponsors
lead

ObsEva SA

INDUSTRY